Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?

Eur Heart J. 2016 May 1;37(17):1353-6. doi: 10.1093/eurheartj/ehw010. Epub 2016 Feb 6.

Authors

Alpo Vuorio¹, Gerald F Watts², Petri T Kovanen³

Affiliations

¹ Mehiläinen Airport Health Center, Lentäjäntie 1 E, Vantaa 00150, Finland alpo.vuorio@gmail.com.
² Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia.
³ Wihuri Research Institute, Helsinki, Finland.

PMID: 26851704
DOI: 10.1093/eurheartj/ehw010

No abstract available

Publication types

Review

MeSH terms

Adolescent
Adult
Age Distribution
Antibodies, Monoclonal, Humanized / therapeutic use
Child
Cholesterol, LDL / metabolism
Coronary Disease / genetics
Female
Heterozygote
Humans
Hyperlipoproteinemia Type II / drug therapy*
Hyperlipoproteinemia Type II / genetics
Male
Middle Aged
Myocardial Infarction / genetics
PCSK9 Inhibitors*
Risk Factors
Sex Distribution
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Cholesterol, LDL
PCSK9 Inhibitors
PCSK9 protein, human